Amgen Inc (AMGN)
Market Closed
28 Mar, 20:00
$
306. 95
+1.18
+0.39%
$
143.25B Market Cap
19.61 P/E Ratio
9% Div Yield
1,768,400 Volume
18.58 Eps
$ 305.77
Previous Close Day Range
304.71 308.17
Year Range
253.3 346.85
Earnings results expected in 31 days
Summary
AMGN closed yesterday higher at $306.95, an increase of 0.39% from Thursday's close, completing a monthly increase of 17.08% or $44.77. Over the past 12 months, AMGN stock gained 8.82%.
AMGN pays dividends to its shareholders, with the most recent payment made on Mar 07, 2025. The next announced payment will be in In 2 months on Jun 06, 2025 for a total of $2.38.
The last earnings report, released on Feb 04, 2025, exceeded the consensus estimates by 0.23%. On average, the company has surpassed earnings expectations by 0.24%, based on the last three reports. The next scheduled earnings report is due on Apr 30, 2025.
The stock of the company had never split.
The company's stock is traded on 13 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track AMGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
AMGN Chart
Loading, please wait...
Amgen Inc Dividends
| AMGN In 4 months Estimated | Quarterly | $2.38 Per Share |
| AMGN In 1 month Announced | Quarterly | $2.38 Per Share |
| AMGN 1 month ago Paid | Quarterly | $2.38 Per Share |
| AMGN 4 months ago Paid | Quarterly | $2.25 Per Share |
| AMGN 7 months ago Paid | Quarterly | $2.25 Per Share |
| AMGN 10 months ago Paid | Quarterly | $2.25 Per Share |
Amgen Inc Earnings
| 30 Apr 2025 (31 Days) Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | 5.08 Cons. EPS | 5.31 EPS |
| 30 Oct 2024 Date | | 5.11 Cons. EPS | 5.58 EPS |
| 29 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | 5 Cons. EPS | - EPS |
| AMGN In 4 months Estimated | Quarterly | $2.38 Per Share |
| AMGN In 1 month Announced | Quarterly | $2.38 Per Share |
| AMGN 1 month ago Paid | Quarterly | $2.38 Per Share |
| AMGN 4 months ago Paid | Quarterly | $2.25 Per Share |
| AMGN 7 months ago Paid | Quarterly | $2.25 Per Share |
| AMGN 10 months ago Paid | Quarterly | $2.25 Per Share |
| 30 Apr 2025 (31 Days) Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | 5.08 Cons. EPS | 5.31 EPS |
| 30 Oct 2024 Date | | 5.11 Cons. EPS | 5.58 EPS |
| 29 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | 5 Cons. EPS | - EPS |
Amgen Inc (AMGN) FAQ
What is the stock price today?
The current price is $306.95.
On which exchange is it traded?
Amgen Inc is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is AMGN.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 143.25B.
What is the earnings per share?
The EPS is 0.
When is the next earnings date?
The next earnings report will release on Apr 30, 2025.
Has Amgen Inc ever had a stock split?
No, there has never been a stock split.
Amgen Inc Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Mr. Robert A. Bradway CEO | NASDAQ (NGS) Exchange | 031162100 Cusip |
| United States Country | 26,700 Employees | 16 May 2025 Last Dividend | 22 Nov 1999 Last Split | 17 Jun 1983 IPO Date |
Overview
Amgen Inc. is a global leader in biotechnology, focusing on the discovery, development, manufacture, and delivery of human therapeutics. The company has a comprehensive portfolio of treatment options targeting various diseases and conditions, ranging from oncology and osteoporosis to cardiovascular diseases and inflammatory disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen serves healthcare providers worldwide, including physicians' clinics, dialysis centers, hospitals, and pharmacies. Its distribution network encompasses pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen’s collaborative efforts extend to several high-profile partnerships with other pharmaceutical giants, including AstraZeneca, Novartis Pharma AG, UCB, Kyowa Kirin Co., Ltd., and BeiGene, Ltd., aiming at the expansion and development of innovative therapies.
Products and Services
- Enbrel - A leading therapy for plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis.
- Otezla - Designed for adults suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease.
- Prolia - Addresses osteoporosis in postmenopausal women.
- XGEVA - Prevents skeletal-related events.
- Repatha - Reduces the risk of myocardial infarction, stroke, and coronary revascularization.
- Nplate - Treats immune thrombocytopenia.
- KYPROLIS - For relapsed or refractory multiple myeloma patients.
- Aranesp - Addresses a lower-than-normal number of red blood cells and anemia.
- EVENITY - A treatment for osteoporosis in postmenopausal for men and women.
- Vectibix - Treats patients with wild-type RAS metastatic colorectal cancer.
- BLINCYTO - For patients with acute lymphoblastic leukemia.
- TEPEZZA - Treats thyroid eye disease.
- KRYSTEXXA - Addresses chronic refractory gout.
- Additional Products - Amgen also markets Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI, covering a wide range of therapeutic areas.
Contact Information
Address: One Amgen Center Drive
Phone: 805 447 1000
Website: https://www.amgen.com
2025 © Marketlog. All Rights Reserved.
